2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 6,444,170 | Feb 21, 2025 |
| BCLS SB Investco, LP | 10% Owner | 6,444,170 | Feb 21, 2025 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 6,444,170 | Feb 21, 2025 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | 6,444,170 | Feb 21, 2025 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | 6,444,170 | Feb 21, 2025 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Feb 18, 2026 | Cumbo Alexander | CEO | Sell | 42.5 | -16,644 | -6.60% | ✗ | $96.9K |
| Feb 13, 2026 | Feb 18, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 46.3 | -4,134 | -5.27% | ✗ | $24.1K |
| Feb 13, 2026 | Feb 18, 2026 | Ganot Ilan | Director | Sell | 46.3 | -2,658 | -1.79% | ✗ | $15.5K |
| Feb 13, 2026 | Feb 18, 2026 | Herzich Paul | Chief Technology Officer | Sell | 46.3 | -3,616 | -4.74% | ✗ | $21.1K |
| Feb 13, 2026 | Feb 18, 2026 | Howton David T | COO | Sell | 46.3 | -7,469 | -6.64% | ✗ | $43.5K |
| Feb 13, 2026 | Feb 18, 2026 | Brooks Gabriel | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2026 | Feb 18, 2026 | Tan Kevin | CFO | Sell | 46.3 | -5,404 | -5.16% | ✗ | $31.5K |
| Feb 4, 2026 | Feb 6, 2026 | Howton David T | COO | Sell | 42.5 | -18,894 | -16.18% | ✗ | $121.7K |
| Feb 4, 2026 | Feb 6, 2026 | Cumbo Alexander | CEO | Sell | 40.0 | -48,913 | -18.05% | ✗ | $315.1K |
| Feb 4, 2026 | Feb 6, 2026 | Ganot Ilan | Director | Sell | 46.3 | -7,205 | -4.77% | ✗ | $46.4K |
| Feb 4, 2026 | Feb 6, 2026 | Tan Kevin | CFO | Sell | 42.5 | -14,783 | -13.56% | ✗ | $95.2K |
| Feb 4, 2026 | Feb 6, 2026 | Brooks Gabriel | Chief Medical Officer | Sell | 42.5 | -12,616 | -13.05% | ✗ | $81.3K |
| Feb 4, 2026 | Feb 6, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 42.5 | -12,348 | -14.94% | ✗ | $79.5K |
| Feb 4, 2026 | Feb 6, 2026 | Herzich Paul | Chief Technology Officer | Sell | 42.5 | -10,905 | -13.64% | ✗ | $70.2K |
| Jan 29, 2026 | Feb 2, 2026 | Tan Kevin | CFO | Sell | 42.5 | -26,837 | -19.76% | ✗ | $172.7K |
| Jan 29, 2026 | Feb 2, 2026 | Cumbo Alexander | CEO | Sell | 40.0 | -80,258 | -22.85% | ✗ | $516.6K |
| Jan 29, 2026 | Feb 2, 2026 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 42.5 | -26,535 | -24.30% | ✗ | $170.8K |
| Jan 29, 2026 | Feb 2, 2026 | Brooks Gabriel | Chief Medical Officer | Sell | 42.5 | -28,335 | -22.66% | ✗ | $182.4K |
| Jan 29, 2026 | Feb 2, 2026 | Howton David T | COO | Sell | 42.5 | -37,771 | -24.44% | ✗ | $243.1K |
| Jan 29, 2026 | Feb 2, 2026 | Herzich Paul | Chief Technology Officer | Sell | 42.5 | -26,250 | -24.71% | ✗ | $169K |
| Jan 31, 2026 | Feb 2, 2026 | Ganot Ilan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 27, 2026 | Jan 30, 2026 | Ganot Ilan | Director | Sell | 50.0 | -191 | -0.52% | ✗ | $1.3K |
| Jan 9, 2026 | Jan 13, 2026 | Tan Kevin | CFO | Sell | 46.3 | -5,704 | -11.01% | ✗ | $30.1K |
| Jan 6, 2026 | Jan 7, 2026 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 3, 2026 | Jan 6, 2026 | Ganot Ilan | Director | Sell | 50.0 | -1,053 | -0.79% | ✗ | $5.7K |
| Dec 2, 2025 | Dec 4, 2025 | Howton David T | COO | Sell | 46.3 | -4,932 | -13.03% | ✗ | $25.2K |
| Dec 2, 2025 | Dec 4, 2025 | Cumbo Alexander | CEO | Sell | 42.5 | -10,808 | -11.72% | ✗ | $55.2K |
| Dec 2, 2025 | Dec 4, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 46.3 | -4,483 | -14.39% | ✗ | $22.9K |
| Dec 2, 2025 | Dec 4, 2025 | Herzich Paul | Chief Technology Officer | Sell | 46.3 | -2,701 | -9.21% | ✗ | $13.8K |
| Nov 10, 2025 | Nov 13, 2025 | Ganot Ilan | Director | Sell | 26.3 | -3,278 | -2.47% | ✗ | $13.5K |
| Oct 18, 2025 | Oct 21, 2025 | Brooks Gabriel | Chief Medical Officer | Sell | 46.3 | -2,895 | -7.89% | ✗ | $17.3K |
| Oct 6, 2025 | Oct 7, 2025 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Ganot Ilan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Howton David T | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Tan Kevin | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Herzich Paul | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Brooks Gabriel | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 14, 2025 | Aug 18, 2025 | Cumbo Alexander | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 6, 2025 | Jul 8, 2025 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 18, 2025 | Keresty Georgia | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Stone Adam Leo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | PERCEPTIVE ADVISORS LLC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Freed Martin I | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Nagendran Sukumar | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Kahn Clare | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Ganot Ilan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Sullivan Lynne Marie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 6, 2025 | Apr 8, 2025 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 11, 2025 | Mar 13, 2025 | Kahn Clare | Director | Buy | 90.0 | +1,860 | 169.09% | ✗ | $9.9K |
| Feb 19, 2025 | Feb 21, 2025 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Buy | 100.0 | +1,000,000 | 24.79% | ✗ | $4M |
| Feb 19, 2025 | Feb 21, 2025 | PERCEPTIVE ADVISORS LLC | Director | Buy | 100.0 | +5,000,000 | 73.17% | ✗ | $20.2M |
| Feb 19, 2025 | Feb 21, 2025 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2025 | Feb 19, 2025 | Adage Capital Management, L.P. | 10% Owner | Buy | 95.0 | +252,545 | 6.32% | ✗ | $1.9M |
| Feb 19, 2025 | Adage Capital Management, L.P. | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 13, 2025 | Feb 18, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 46.3 | -3,079 | -13.77% | ✗ | $12.2K |
| Feb 13, 2025 | Feb 18, 2025 | Brooks Gabriel | Chief Medical Officer | Sell | 46.3 | -3,256 | -12.49% | ✗ | $12.9K |
| Feb 13, 2025 | Feb 18, 2025 | Tan Kevin | CFO | Sell | 46.3 | -3,164 | -8.93% | ✗ | $12.5K |
| Feb 13, 2025 | Feb 18, 2025 | Howton David T | COO | Sell | 46.3 | -5,561 | -18.32% | ✗ | $22K |
| Feb 13, 2025 | Feb 18, 2025 | Herzich Paul | Chief Technology Officer | Sell | 46.3 | -2,688 | -12.75% | ✗ | $10.6K |
| Feb 13, 2025 | Feb 18, 2025 | Cumbo Alexander | CEO | Sell | 46.3 | -11,365 | -15.77% | ✗ | $45K |
| Feb 13, 2025 | Feb 18, 2025 | Ganot Ilan | Director | Sell | 47.5 | -1,711 | -1.27% | ✗ | $6.8K |
| Jan 31, 2025 | Feb 11, 2025 | Hanrahan Jessie | Chief Regulatory Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Herzich Paul | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Ganot Ilan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Tan Kevin | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Brooks Gabriel | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Howton David T | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2025 | Feb 11, 2025 | Cumbo Alexander | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 27, 2025 | Jan 29, 2025 | Ganot Ilan | Director | Sell | 52.5 | -144 | -0.46% | ✗ | $447.8 |
| Jan 9, 2025 | Jan 13, 2025 | Tan Kevin | CFO | Sell | 46.3 | -4,073 | -14.11% | ✗ | $15.8K |
| Jan 3, 2025 | Jan 7, 2025 | Ganot Ilan | Director | Sell | 50.0 | -1,056 | -0.83% | ✗ | $4.6K |
| Jan 3, 2025 | Jan 7, 2025 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 2, 2024 | Dec 4, 2024 | Hanrahan Jessie | Chief Regulatory Officer | Sell | 46.3 | -4,610 | -24.46% | ✗ | $25.8K |
| Dec 2, 2024 | Dec 4, 2024 | Cumbo Alexander | CEO | Sell | 42.5 | -11,114 | -22.41% | ✗ | $62.2K |
| Dec 2, 2024 | Dec 4, 2024 | Howton David T | COO | Sell | 46.3 | -5,072 | -24.46% | ✗ | $28.4K |
| Dec 2, 2024 | Dec 4, 2024 | Herzich Paul | Chief Technology Officer | Sell | 46.3 | -2,777 | -18.56% | ✗ | $15.6K |
| Jun 11, 2024 | Nov 19, 2024 | Stone Adam Leo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Nov 19, 2024 | PERCEPTIVE ADVISORS LLC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 18, 2024 | Oct 22, 2024 | Brooks Gabriel | Chief Medical Officer | Sell | 46.3 | -2,923 | -21.03% | ✗ | $19K |
| Oct 3, 2024 | Oct 4, 2024 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 3, 2024 | Jul 5, 2024 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Keresty Georgia | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Sullivan Lynne Marie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Freed Martin I | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Nagendran Sukumar | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Kahn Clare | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 11, 2024 | Jun 13, 2024 | Ganot Ilan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 7, 2024 | Jun 11, 2024 | Kahn Clare | Director | Buy | 90.0 | +1,100 | 100.00% | ✗ | $8.4K |
| May 2, 2024 | May 6, 2024 | Ganot Ilan | Director | Sell | 52.5 | -462 | -0.37% | ✗ | $4.8K |
| Apr 3, 2024 | Apr 5, 2024 | SMITH IAN F | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Hanrahan Jessie | Chief Regulatory Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Cumbo Alexander | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Brooks Gabriel | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Tan Kevin | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Howton David T | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Marlowe Jennifer | CSO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 16, 2024 | Herzich Paul | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |